Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 158-164

  Toyama, Kensuke ^a,b   Sugiyama, Seigo ^a   Oka, Hideki ^b   Iwasaki, Yuri ^b   Sumida, Hitoshi ^c   Tanaka, Tomoko ^c   Tayama, Shinji ^b,c   Jinnouchi, Hideaki ^c   Matsui, Kunihiko ^d   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Health Insurance Hitoyoshi General Hospital   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^d YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Coenzyme Q10; Coronary artery disease; Exercise; High density lipoprotein cholesterol; Statins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; UBIDECARENONE;

ADULT; AEROBIC EXERCISE; AGE; AGED; ARTICLE; BODY MASS; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXERCISE; EXERCISE INTENSITY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING;

AGED; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIMIDINES; PYRROLES; RISK; SMOKING; SULFONAMIDES; UBIQUINONE;

EID: 79957607586     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.050     Document Type: Article

References (31)

1. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
2. Kalen A., Appelkvist E.L., Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids 1989, 24:579-584.
3. Belardinelli R., Mucaj A., Lacalaprice F., et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006, 27:2675-2681.
4. Hanaki Y., Sugiyama S., Ozawa T., Ohno M. Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factor. N Engl J Med 1991, 325:814-815.
5. Singh R.B., Neki N.S., Kartikey K., et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003, 246:75-82.
6. Mabuchi H., Nohara A., Kobayashi J., et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007, 195:e182-189.
7. Hausenloy D.J., Yellon D.M. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008, 94:706-714.
8. Cziraky M.J., Watson K.E., Talbert R.L. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manage Care Pharm 2008, 14:S3-28. quiz S30-21.
9. Natarajan P., Ray K.K., Cannon C.P. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010, 55:1283-1299.
10. Toyama K., Sugiyama S., Oka H., Sumida H., Ogawa H. Exercise therapy correlates with improving renal function through modifying lipid metabolism in patients with cardiovascular disease and chronic kidney disease. J Cardiol 2010, 56:142-146.
11. Taylor R.S., Brown A., Ebrahim S., et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004, 116:682-692.
12. Kelley G.A., Kelley K.S., Franklin B. Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. J Cardiopulm Rehabil 2006, 26:131-139. quiz 140-131, discussion 142-134.
13. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492.
14. Barter P.J., Brandrup-Wognsen G., Palmer M.K., Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 2010, 51:1546-1553.
15. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases. J Atheroscler Thromb 2007;5-57.
16. Yamashita S., Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem 1997, 250:66-73.
17. Beaver W.L., Wasserman K., Whipp B.J. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986, 60:2020-2027.
18. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
19. Gordon T, Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977, 62:707-714.
20. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
21. Grover S.A., Kaouache M., Joseph L., Barter P., Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Int Med 2009, 169:1775-1780.
22. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316.
23. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
24. Ichihara K., Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002, 359:2195-2198.
25. Avis H.J., Hargreaves I.P., Ruiter J.P., Land J.M., Wanders R.J., Wijburg F.A. Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia. J Pediatr 2010.
26. Kaufmann P., Torok M., Zahno A., Waldhauser K.M., Brecht K., Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006, 63:2415-2425.
27. Pierno S., De Luca A., Liantonio A., Camerino C., Conte Camerino D. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur J Pharmacol 1999, 364:43-48.
28. Stahle J.A., Vunta H., Channa Reddy C., Sandeep Prabhu K. Regulation of expression of apolipoprotein A-I by selenium status in human liver hepatoblastoma cells. Eur J Nutr 2009, 48:283-290.
29. Sugiyama S., Fukushima H., Kugiyama K., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-51.
30. Tsutamoto T., Yamaji M., Kawahara C., et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail 2009, 11:1195-1201.
31. Demyanets S., Kaun C., Pfaffenberger S., et al. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem Pharmacol 2006, 71:1324-1330.